Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 2,300 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 2,300 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $6.08, for a total value of $13,984.00. Following the completion of the transaction, the insider owned 15,370,009 shares in the company, valued at approximately $93,449,654.72. The trade was a 0.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Trading Down 2.4%

Shares of VIR stock opened at $5.72 on Wednesday. The stock has a market capitalization of $794.62 million, a P/E ratio of -1.43 and a beta of 1.27. The firm’s 50 day moving average is $5.08 and its 200 day moving average is $5.28. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The company’s revenue was down 60.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.02) EPS. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their target price for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th. Raymond James Financial assumed coverage on Vir Biotechnology in a research report on Friday, July 11th. They issued an “outperform” rating on the stock. Finally, Evercore ISI assumed coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $17.30.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Clarius Group LLC raised its stake in shares of Vir Biotechnology by 0.3% during the third quarter. Clarius Group LLC now owns 619,312 shares of the company’s stock worth $3,536,000 after acquiring an additional 1,777 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Vir Biotechnology by 26.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after purchasing an additional 2,171 shares during the period. Rhumbline Advisers raised its position in Vir Biotechnology by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock worth $1,154,000 after purchasing an additional 2,300 shares during the period. Focus Partners Wealth increased its holdings in shares of Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after buying an additional 2,566 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Vir Biotechnology by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock worth $248,000 after buying an additional 3,209 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).